Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. (NYSE: CAH) generates a steady flow of news as a major participant in pharmaceutical distribution, medical products manufacturing and distribution, home-health services, and specialty healthcare support. This CAH news page aggregates company press releases and third-party coverage so readers can follow how Cardinal Health’s strategy, operations, and capital decisions evolve over time.
Recent news highlights include updates on financial performance and outlook, such as first-quarter fiscal 2026 results reported via Form 8-K and subsequent press releases, where Cardinal Health discussed revenue growth, segment profit trends, and revised non-GAAP earnings guidance. The company also issues announcements about upcoming earnings releases and webcasts, providing dates and times for quarterly and annual results discussions.
Cardinal Health’s news flow also covers strategic initiatives and acquisitions. For example, the company has reported on its plan and subsequent completion of the acquisition of Solaris Health, described as a leading urology management services organization that adds scale to The Specialty Alliance. Other updates discuss growth in Specialty revenues, expansion of MSO platforms, and the role of BioPharma Solutions and Sonexus™ Access and Patient Support in serving manufacturer partners and patients.
Operational and infrastructure developments are another key news theme. Cardinal Health has announced a new flagship Pharmaceutical and Specialty Solutions forward distribution center in Indianapolis, Indiana, a Consumer Health Logistics Center in Ohio, and new and planned at-Home Solutions distribution centers in Texas and California, all emphasizing automation and technology to support distribution and logistics.
Investors and observers can also find capital markets and governance updates in Cardinal Health’s news, including public offerings of notes to fund acquisitions, quarterly dividend declarations approved by the Board of Directors, and information related to annual shareholder meetings. Bookmark this page to review Cardinal Health (CAH) news across earnings, acquisitions, infrastructure investments, and governance developments in one place.
Cue Health Inc. (Nasdaq: HLTH) has partnered with Cardinal Health (NYSE: CAH) to expand distribution of its COVID-19 tests across traditional and non-traditional healthcare settings. This collaboration aims to enhance the availability of Cue's nucleic acid amplification tests, which have shown 97.8% concordance with PCR tests, and the innovative at-home test, the first of its kind to gain Emergency Use Authorization from the FDA. Both professional and OTC/home test kits will be available, supporting healthcare providers’ evolving diagnostic needs.
Summary not available.
Cardinal Health (NYSE: CAH) announced on February 9, 2022, a partnership with Kinaxis to enhance its medical supply chain operations. The Kinaxis RapidResponse platform will increase product visibility and improve supply chain agility. Initial implementation will focus on Cardinal Health at-Home Solutions, with a full rollout expected by the end of 2023. This integration aims to provide real-time insights, enabling better risk management and inventory capabilities while aiding in proactive decision-making for customer demand and supply balance.
Cardinal Health (NYSE: CAH) has announced a quarterly dividend of $0.4908 per share, reflecting its ongoing commitment to shareholder returns. This dividend will be payable on April 15, 2022, to shareholders of record as of April 1, 2022. With extensive operations across over 30 countries and approximately 44,000 employees, Cardinal Health plays a vital role in healthcare by providing pharmaceutical distribution and medical products. This announcement signifies a continued effort to maintain steady income for investors.
Cardinal Health released its 2022 Biosimilars Report, highlighting the current state and future prospects of biosimilars in the U.S. The report suggests that 2022 may be pivotal as biosimilars expand into new therapeutic areas. It presents survey data from over 320 healthcare providers, revealing a moderate readiness to discuss biosimilars among pharmacists, with only 40% feeling adequately prepared. The report includes anticipated market trends, payer coverage, and predictions for the biosimilars landscape through 2029.
Cardinal Health (CAH) reported its Q2 FY22 revenues at $45.5 billion, up 9% year-over-year, despite a GAAP operating loss of $950 million due to a $1.3 billion goodwill impairment in the Medical segment. Non-GAAP operating earnings dropped 26% to $467 million, reflecting the impact of inflation and supply chain issues. The company revised its FY2022 non-GAAP diluted EPS guidance to $5.15 to $5.50, acknowledging a significant decline in Medical segment profits and heightened inflationary pressures.
Ember Technologies and Cardinal Health (CAH) have announced a groundbreaking partnership to introduce the Ember Cube, the world's first self-refrigerated, cloud-based shipping box designed for temperature-sensitive medicines. This innovative shipping solution addresses the growing need for secure, sustainable cold chain logistics, as global spending is projected to exceed $21 billion by 2024. The Ember Cube features advanced tracking capabilities, real-time temperature monitoring, and reusable technology, significantly reducing waste from traditional packaging methods. A customer pilot is set for 2022.
Summary not available.
Cardinal Health (NYSE: CAH) reported a fiscal year 2022 update, projecting an additional $150 million to $175 million hit to Medical segment profits due to ongoing inflation and supply chain constraints. This translates to an estimated $0.40 to $0.45 loss per share in non-GAAP diluted EPS. The company reassured that other financial expectations remain unchanged. Cardinal Health is committed to enhancing its Medical segment through operational simplification and growth investments. A presentation at the J.P. Morgan Healthcare Conference is scheduled for today.
Cardinal Health (NYSE: CAH) will release its second-quarter financial results for fiscal year 2022 on February 3 before the market opens. The company will host a webcast at 8:30 a.m. Eastern to discuss these results. Additionally, CEO Mike Kaufmann is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on January 10. The webcast and presentation slides will be accessible on the Investor Relations page until February 2, 2023.